News
URGN
34.49
-1.88%
-0.66
Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Humana (HUM)
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN), Genmab (GMAB) and Neogen (NEOG)
TipRanks · 6d ago
UroGen Pharma Price Target Maintained With a $75.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target
Benzinga · 6d ago
UroGen gets FDA review for new bladder cancer therapy
Seeking Alpha · 6d ago
UroGen Pharma announces FDA acceptance of UGN-103 NDA
TipRanks · 6d ago
Weekly Report: what happened at URGN last week (1012-1016)?
Weekly Report · 6d ago
UroGen Pharma management to meet with Oppenheimer
TipRanks · 10/14 19:50
UroGen Pharma: An Emerging GARP Stock
Seeking Alpha · 10/13 11:09
Weekly Report: what happened at URGN last week (1005-1009)?
Weekly Report · 10/12 10:20
After Hours Most Active for Oct 9, 2026 : FTXR, NVDA, BKD, GRAB, TRVI, URGN, INDV, LUV, WFC, ESI, OSG, BAC
NASDAQ · 10/09 20:24
UroGen Pharma falls -12.8%
TipRanks · 10/08 16:05
Weekly Report: what happened at URGN last week (0928-1002)?
Weekly Report · 10/05 10:19
Weekly Report: what happened at URGN last week (0921-0925)?
Weekly Report · 09/28 10:14
UroGen Pharma management to meet with Piper Sandler
TipRanks · 09/21 18:55
Weekly Report: what happened at URGN last week (0914-0918)?
Weekly Report · 09/21 10:15
Weekly Report: what happened at URGN last week (0907-0911)?
Weekly Report · 09/14 10:20
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Barron‘s · 09/09 14:44
Urogen Pharma: Upside After Bladder Cancer Launch
Seeking Alpha · 09/09 13:54
Weekly Report: what happened at URGN last week (0831-0904)?
Weekly Report · 09/07 10:13
More
Webull provides a variety of real-time URGN stock news. You can receive the latest news about Urogen Pharma through multiple platforms. This information may help you make smarter investment decisions.
About URGN
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).